Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALIM Alimera Sciences	$5.54	$5.55	$2.61 ▼ $5.65	$290.24M	1.25	376,318 shs	N/A
NTLA Intellia Therapeutics	$10.29 -4.1%	$10.92	$5.90 ▼ $24.16	$1.10B	2.31	4.12 million shs	5.18 million shs
TLRY Tilray Brands	$1.06 -7.0%	$0.61	$0.35 ▼ $1.95	$1.17B	1.85	40.75 million shs	42.33 million shs
XERS Xeris Biopharma	$7.36	$5.28	$2.48 ▼ $7.79	$1.19B	0.65	2.57 million shs	2.04 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALIM Alimera Sciences	0.00%	0.00%	0.00%	0.00%	-0.72%
NTLA Intellia Therapeutics	-2.37%	-0.09%	-11.03%	+10.96%	-52.59%
TLRY Tilray Brands	+10.68%	+24.05%	+83.49%	+151.71%	-41.24%
XERS Xeris Biopharma	-4.17%	+2.22%	+44.03%	+44.88%	+173.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALIM Alimera Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	4.4474 of 5 stars	4.3	1.0	0.0	4.7	2.5	2.5	0.6
TLRY Tilray Brands	2.5649 of 5 stars	3.1	1.0	0.0	0.0	3.8	1.7	1.3
XERS Xeris Biopharma	3.4026 of 5 stars	1.4	3.0	0.0	4.2	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALIM Alimera Sciences	0.00	N/A	N/A	N/A
NTLA Intellia Therapeutics	2.58	Moderate Buy	$29.05	182.34% Upside
TLRY Tilray Brands	2.20	Hold	$1.92	80.82% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.58	-10.55% Downside

Current Analyst Ratings Breakdown

Latest ALIM, XERS, NTLA, and TLRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/12/2025	XERS Xeris Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
8/11/2025	NTLA Intellia Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $60.00
8/8/2025	NTLA Intellia Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $45.00
8/8/2025	NTLA Intellia Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
8/8/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
7/29/2025	TLRY Tilray Brands	Zelman & Associates Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALIM Alimera Sciences	$99.68M	2.91	N/A	N/A	$0.88 per share	6.30
NTLA Intellia Therapeutics	$52.86M	20.90	N/A	N/A	$8.56 per share	1.20
TLRY Tilray Brands	$210.48M	5.54	$0.15 per share	7.13	$1.40 per share	0.76
XERS Xeris Biopharma	$246.03M	4.83	N/A	N/A	($0.20) per share	-36.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALIM Alimera Sciences	-$20.13M	-$1.57	N/A	26.38	N/A	-14.74%	-33.70%	-9.63%	N/A
NTLA Intellia Therapeutics	-$519.02M	-$4.69	N/A	N/A	N/A	-908.48%	-57.48%	-45.04%	11/6/2025 (Estimated)
TLRY Tilray Brands	-$2.19B	-$2.31	N/A	N/A	N/A	-265.69%	-6.83%	-5.45%	10/9/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.21	N/A	N/A	N/A	-13.01%	N/A	-8.00%	N/A

Latest ALIM, XERS, NTLA, and TLRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NTLA Intellia Therapeutics	-$1.03	-$0.99	+$0.04	-$0.98	$12.26 million	$14.25 million
8/7/2025	Q2 2025	XERS Xeris Biopharma	-$0.03	-$0.01	+$0.02	-$0.01	$64.58 million	$67.71 million
7/28/2025	Q4 2025	TLRY Tilray Brands	-$0.03	$0.02	+$0.05	-$1.30	$250.41 million	$224.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALIM Alimera Sciences	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALIM Alimera Sciences	1.80	2.79	2.62
NTLA Intellia Therapeutics	N/A	5.19	5.19
TLRY Tilray Brands	0.20	2.46	1.49
XERS Xeris Biopharma	N/A	1.95	1.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALIM Alimera Sciences	99.83%
NTLA Intellia Therapeutics	88.77%
TLRY Tilray Brands	9.35%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
ALIM Alimera Sciences	31.40%
NTLA Intellia Therapeutics	3.10%
TLRY Tilray Brands	0.60%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALIM Alimera Sciences	150	52.39 million	35.94 million	Optionable
NTLA Intellia Therapeutics	600	107.35 million	104.02 million	Optionable
TLRY Tilray Brands	2,842	1.10 billion	1.09 billion	Optionable
XERS Xeris Biopharma	290	161.48 million	154.12 million	Optionable

ALIM, XERS, NTLA, and TLRY Headlines

Recent News About These Companies

Deutsche Bank AG Grows Position in Xeris Biopharma Holdings, Inc. $XERS

August 19 at 4:01 AM | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Rating of "Moderate Buy" by Analysts

August 18 at 2:12 AM | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director John Johnson Sells 107,500 Shares

August 17 at 7:31 PM | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Sets New 52-Week High - Here's Why

August 17 at 4:45 PM | marketbeat.com

John Johnson Sells 107,500 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock

August 16 at 8:05 AM | insidertrades.com

HC Wainwright Estimates Xeris Biopharma Q3 Earnings

August 16 at 7:57 AM | marketbeat.com

HC Wainwright Comments on Xeris Biopharma Q3 Earnings

August 16 at 2:15 AM | americanbankingnews.com

Insider Selling: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Sells 42,500 Shares of Stock

August 15, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Purchases 418,139 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

August 15, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Sells $309,400.00 in Stock

August 14, 2025 | insidertrades.com

Xeris Biopharma (NASDAQ:XERS) Rating Increased to Buy at HC Wainwright

August 14, 2025 | americanbankingnews.com

Xeris Biopharma's (XERS) "Buy" Rating Reaffirmed at HC Wainwright

August 13, 2025 | marketbeat.com

Informed Momentum Co LLC Grows Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

August 13, 2025 | marketbeat.com

Xeris Biopharma assumed with a Buy at H.C. Wainwright

August 12, 2025 | msn.com

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

August 12, 2025 | zacks.com

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

August 12, 2025 | zacks.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is Knott David M Jr's 7th Largest Position

August 12, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Raised to Strong-Buy at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Releases Earnings Results, Beats Expectations By $0.02 EPS

August 10, 2025 | marketbeat.com

Critical Survey: Xeris Biopharma (NASDAQ:XERS) versus CASI Pharmaceuticals (NASDAQ:CASI)

August 10, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Upgraded to "Strong-Buy" at Wall Street Zen

August 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALIM, XERS, NTLA, and TLRY Company Descriptions

Alimera Sciences NASDAQ:ALIM

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Intellia Therapeutics NASDAQ:NTLA

$10.29 -0.44 (-4.10%)

Closing price 04:00 PM Eastern

Extended Trading

$10.32 +0.04 (+0.34%)

As of 07:06 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Tilray Brands NASDAQ:TLRY

$1.06 -0.08 (-7.02%)

Closing price 04:00 PM Eastern

Extended Trading

$1.06 -0.01 (-0.47%)

As of 07:15 PM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

Xeris Biopharma NASDAQ:XERS

$7.36 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.34 -0.03 (-0.34%)

As of 05:53 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time